3 Min Read
DHAKA (Reuters) - India’s Bharat Biotech has applied to conduct trials in Bangladesh for its coronavirus vaccine recently approved for emergency use at home, a senior official at Bangladesh’s main medical research body told Reuters.
FILE PHOTO: Indian Health Minister Harsh Vardhan holds a dose of Bharat Biotech s COVID-19 vaccine called COVAXIN, during a vaccination campaign at All India Institute of Medical Sciences (AIIMS) hospital in New Delhi, India, January 16, 2021. REUTERS/Adnan Abidi
If allowed to go ahead, this would be the first trial of any coronavirus vaccine in Bangladesh and could give the densely-populated country of more than 160 million faster access to the shot for mass use.
Bharat Biotech seeks nod to conduct Covaxin trials in Bangladesh, Myanmar
Successful efficacy trials would reinforce India’s credentials as a major vaccine producer globally
(PTI)
Share Via
Read Full Story
NEW DELHI :
Hyderabad-based Bharat Biotech Ltd whose vaccine is among two approved by the Indian government for mass inoculation against covid-19 has sought permission from the governments in Bangladesh and Myanmar to conduct clinical trials, said three people familiar with the developments.
The move is seen as a step towards Bharat Biotech pitching its Covaxin vaccine as a viable option to combat the pandemic, opening up new markets.
TRENDING STORIESSee All
Bharat Biotech applies for COVID-19 vaccine trials in Bangladesh medicaldialogues.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicaldialogues.in Daily Mail and Mail on Sunday newspapers.
If allowed to go ahead, this would be the first trial of any coronavirus vaccine in Bangladesh and could give the densely-populated country of more than 160 million faster access to the shot for mass use.
India's Bharat Biotech has applied to conduct trials in Bangladesh for its coronavirus vaccine recently approved for emergency use at home, a senior official at Bangladesh's main medical research body told Reuters. If allowed to go ahead, this would be the first trial of any coronavirus vaccine in Bangladesh and could give the densely-populated country of more than 160 million